Mirodenafil - AriBio
Alternative Names: AR-1001Latest Information Update: 28 Sep 2025
At a glance
- Originator AriBio
- Class Alcohols; Antidementias; Antiparkinsonians; Anxiolytics; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Pyrimidinones; Pyrroles; Small molecules; Sulfones; Vascular disorder therapies
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Alzheimer's disease
- Phase I Lewy body disease; Post-traumatic stress disorders
- No development reported Parkinson's disease; Stroke
- Discontinued Dementia
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for phase-I development in Stroke in South Korea
- 28 Sep 2025 No recent reports of development identified for preclinical development in Parkinson's-disease in South Korea
- 18 Sep 2025 Discontinued - Phase-I for Dementia (unspecified route)